Clinicopathological characteristics of triple-negative breast cancers
- 193 Downloads
Triple-negative breast cancer (TNBC) is defined as a group of breast carcinomas that are negative for expression of hormone receptors and HER2. Although patients with TNBC tend to have a poor prognosis, only chemotherapy is expected to be effective because no therapeutic targets have yet been established. DNA microarray analyses have proved that TNBCs are composed of the basal-like subtype and normal breast (or unclassified) subtype, the former being correlated with an aggressive clinical course. Histological types of TNBCs are reported to be common with those of basal-like subtype, comprising high-grade invasive ductal carcinoma, no special type [solid-tubular carcinoma (or atypical medullary carcinoma), invasive ductal carcinoma with a large central acellular zone], typical medullary carcinoma, and metaplastic carcinomas. The basal-like subtype is characterized by the expression of myoepithelial/basal markers and molecular changes including TP53 gene mutations, BRCA1 inactivation, and many chromosomal alterations. New target molecules for the treatment of TNBCs are under extensive investigation, and their clinical application is awaited.
KeywordsBasal-like subtype BRCA1 Histopathology p53 Triple-negative breast cancer
This work was supported in part by a grant-in-aid for cancer research from the Ministry of Health, Labor, and Welfare, Japan, and a research grant from the Princess Takamatsu Cancer Research Fund.
Conflict of interest statement
The authors indicate no conflict of interest in this study.
- 9.Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.PubMedCrossRefGoogle Scholar
- 15.Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Kouno T, et al. Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer. Proc Am Soc Clin Oncol. 2008;45(Part I):559Google Scholar
- 18.Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, Sastre-Garau X, Kaaks R. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, et al., editors. World health organization classification of tumours. Pathology & genetics. Tumours of the breast and female genital organs. Lyon: IARC Press; 2003. p. 13–59.Google Scholar
- 21.The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer. 16th ed. Tokyo: Kanehara Shuppan; 2008.Google Scholar
- 30.Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, et al. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007;13:90–101.PubMedCrossRefGoogle Scholar
- 36.Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.Google Scholar
- 37.Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:189–91.Google Scholar